Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Ps Multiple | 1.3x - 1.4x | 1.4x |
| Selected Fwd Ps Multiple | 1.2x - 1.3x | 1.3x |
| Fair Value | €1.09 - €1.20 | €1.14 |
| Upside | 13.8% - 25.8% | 19.8% |
| Benchmarks | Ticker | Full Ticker |
|---|---|---|
| GSK plc | - | BMV:GSK1N |
| Sanofi | - | BMV:SAN1N |
| Bayer Aktiengesellschaft | - | BMV:BAYNN |
| Pfizer Inc. | - | BMV:PFE* |
| Perrigo Company plc | - | BMV:PRGON |
| Genomma Lab Internacional, S.A.B. de C.V. | - | DB:GEKA |
| Select Price / LTM Sales Ratio | ||||||||
| Benchmark Companies | ||||||||
| GSK1 N | SAN1 N | BAYN N | PFE * | PRGO N | GEKA | |||
| BMV:GSK1N | BMV:SAN1N | BMV:BAYNN | BMV:PFE* | BMV:PRGON | DB:GEKA | |||
| Historical Sales Growth | ||||||||
| 5Y CAGR | -1.5% | 3.3% | 1.4% | 9.2% | 2.5% | 7.9% | ||
| 3Y CAGR | 8.3% | 4.2% | 1.9% | -7.8% | 1.9% | 6.3% | ||
| Latest Twelve Months | 3.5% | 7.7% | -2.2% | 6.8% | -6.1% | 13.0% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 24.5% | 18.1% | -3.4% | 22.0% | -2.2% | 8.5% | ||
| Prior Fiscal Year | 16.2% | 12.3% | -6.2% | 3.6% | -0.1% | 6.6% | ||
| Latest Fiscal Year | 8.2% | 12.4% | -5.5% | 12.6% | -3.7% | 11.5% | ||
| Latest Twelve Months | 8.2% | 12.4% | -5.5% | 12.6% | -3.7% | 11.5% | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 7.8x | 10.2x | 5.5x | 7.3x | 8.9x | 6.0x | ||
| Price / LTM Sales | 1.7x | 2.5x | 0.4x | 2.0x | 0.8x | 1.2x | ||
| LTM P/E Ratio | 21.0x | 20.2x | -8.1x | 15.7x | -21.5x | 10.2x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/S Ratio | 0.4x | 1.7x | 2.5x | |||||
| Historical LTM P/S Ratio | 0.8x | 1.2x | 1.5x | |||||
| Selected Price / Sales Multiple | 1.3x | 1.4x | 1.4x | |||||
| (x) LTM Sales | 18,607 | 18,607 | 18,607 | |||||
| (=) Equity Value | 24,050 | 25,316 | 26,582 | |||||
| (/) Shares Outstanding | 977.8 | 977.8 | 977.8 | |||||
| Implied Value Range | 24.60 | 25.89 | 27.19 | |||||
| FX Rate: MXN/EUR | 22.7 | 22.7 | 22.7 | Market Price | ||||
| Implied Value Range (Trading Cur) | 1.08 | 1.14 | 1.20 | 0.96 | ||||
| Upside / (Downside) | 13.4% | 19.4% | 25.4% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | GSK1 N | SAN1 N | BAYN N | PFE * | PRGO N | GEKA | |
| Value of Common Equity | 61,271 | 160,740 | 28,260 | 124,348 | 2,874 | 21,201 | |
| (/) Shares Outstanding | 4,526.3 | 1,694.8 | 1,303.6 | 5,671.5 | 102.7 | 977.8 | |
| Implied Stock Price | 13.54 | 94.84 | 21.68 | 21.93 | 27.98 | 21.68 | |
| FX Conversion Rate to Trading Currency | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 22.71 | |
| Implied Stock Price (Trading Cur) | 356.95 | 2,153.45 | 492.21 | 432.25 | 551.64 | 0.96 | |
| Trading Currency | MXN | MXN | MXN | MXN | MXN | EUR | |
| FX Rate to Reporting Currency | 0.04 | 0.04 | 0.04 | 0.05 | 0.05 | 22.71 | |